Involvement of leukotactin-1, a novel CC chemokine, in human atherosclerosis

Yu, Rina; Kim, Chu-Sook; Kawada, Teruo; Kwon, Tae-Won; Lim, Tae‐Hwan; Kim, Young‐Wook; Kwon, Byoung Soo

doi:10.1016/j.atherosclerosis.2003.11.024

Cited by 31 publications

(27 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We showed that LZIP modulates MCP-1-mediated monocyte chemotactic activity and Lkn-1-mediated chemotaxis. MCP-1 and Lkn-1 are known chemokines that are involved in atherosclerosis (Gerard and Rollins, 2001;Yu et al, 2004). Since LZIP did not affect the chemotactic activity of MIP-1α, LZIP possibly participates in the development of atherosclerosis via an increase in CCR2 and CCR1 expressions and subsequent induction of the chemotactic activities of MCP-1 and Lkn-1.…”

Section: Discussionmentioning

confidence: 99%

“…The action of chemokines is mediated by their receptors, a family of seven transmembrane G-protein-coupled receptors (Gerard and Rollins, 2001). Evidence suggests that chemokines and their receptors are involved in development of inflammatory diseases including atherosclerosis (Nelken et al, 1991;Gu et al, 1998;Dawson et al, 1999;Reape and Groot, 1999;Yu et al, 2004;Ko et al, 2007).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Human LZIP induces monocyte CC chemokine receptor 2 expression leading to enhancement of monocyte chemoattractant protein 1/CCL2-induced cell migration

et al. 2008

View full text Add to dashboard Cite

Chemokines and chemokine receptors play a role in migration of circulating leukocytes to the region of inflammation. Human LZIP is an uncharacterized transcription factor and is known to participate in leukotactin (Lkn)-1/CCL15-induced cell migration. We investigated the role of human LZIP in expression of CC chemokine receptors (CCRs) and its involvement in monocyte migration. RNase protection analysis showed that LZIP increased mRNA expression of CCR2 and CCR1 in THP-1 cells. Surface expressions of both CCR2 and CCR1 were also increased by LZIP. Results from an electrophoretic mobility shift assay showed that LZIP binds to the C/EBP element in the CCR2 promoter. LZIP also enhanced the chemotactic activities of monocyte chemoattractant protein-1/CCL2 and Lkn-1. These results suggest that LZIP regulates expression of chemokine receptors that are involved in monocyte migration.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Human LZIP induces monocyte CC chemokine receptor 2 expression leading to enhancement of monocyte chemoattractant protein 1/CCL2-induced cell migration

et al. 2008

View full text Add to dashboard Cite

show abstract

“…11 Chemokines such as MCP-1, IL-8 and leukotactin-1 also play a pivotal role in the development of atherosclerosis by enhancing adhesion molecules on leukocytes and endothelial cells, as well as inducing leukocyte infiltration into the vascular subendothelial area. 13,14 Recent studies have shown that visceral adipose tissue releases more than the subcutaneous and circulating IL-8 is elevated in obesity. 15,16 These findings suggest the possibility that the elevation of chemokines with expanding adiposity contributes to obesity-related pathologies such as diabetes and atherosclerosis.…”

Section: Introductionmentioning

confidence: 99%

Circulating levels of MCP-1 and IL-8 are elevated in human obese subjects and associated with obesity-related parameters

et al. 2006

View full text Add to dashboard Cite

Background: Chemotactic cytokines, referred to as chemokines, play an important role in leukocyte trafficking. The circulating levels of chemokines have been shown to increase in inflammatory processes including obesity-related pathologies (e.g. atherosclerosis and diabetes). However, little is currently known about the relationship between chemokines and human obesity. In the present study, we investigated the circulating levels of selected chemokines (monocyte chemoattractant protein-1 (MCP-1), macrophage inflammatory protein-1a (MIP-1a), leukotactin-1, interleukin-8 (IL-8)) and the association between the chemokine levels and obesity-related parameters: body mass index (BMI), waist circumference, fasting glucose and insulin levels, lipids profile, and the level of C-reactive protein (CRP). Methods: A total of 100 subjects, 50 obese (BMIX25 kg/m 2 ) and 50 who were not obese (BMIo25 kg/m 2 ) participated in the present study. The levels of chemokines and CRP were measured in a fasting state serum by sandwich enzyme-linked immunosorbent assay. Total cholesterol, high-density lipoprotein (HDL)-cholesterol, triglyceride, glucose, and insulin levels were measured by enzymatic analysis and immunoassay. Results: The circulating levels of MCP-1 and IL-8 in the serum were significantly (Po0.05) higher in obese subjects (BMI430 kg/ m 2 ) compared with those of nonobese controls (BMIo25 kg/m 2 ). The levels of CRP were positively correlated with BMI (Po0.001) or waist circumference (Po0.0001). The levels of MCP-1 and IL-8 were positively related to BMI (MCP-1, Po0.02; IL-8, Po0.01) and/or waist circumference (MCP-1, Po0.009; IL-8, Po0.03). The levels of MCP-1 were positively related to the levels of CRP (Po0.007) or interleukin-6 (IL-6) (Po0.0001), and negatively related to the levels of HDL-cholesterol (Po0.01). Homeostasis model assessment (HOMA) score was positively related to the levels of MCP-1 (Po0.02) or IL-8 (Po0.03) in obese subject. Discussion: Our data demonstrated that the circulating levels of MCP-1 and IL-8 are related to obesity-related parameters such as BMI, waist circumference, CRP, IL-6, HOMA and HDL-cholesterol. These findings suggest that the circulating MCP-1 and/or IL-8 may be a potential candidate linking obesity with obesity-related metabolic complications such as atherosclerosis and diabetes.

show abstract

“…Authors have drawn attention to the fact that IL-8 plays a role in the pathogenesis of type 2 diabetes and of atherosclerosis [122]. Significantly higher circulating levels of IL-8 have been found in patients with heart failure and metabolic syndrome compared to patients with heart failure without metabolic syndrome [123].…”

Section: Interleukin-8 (Il-8)mentioning

confidence: 99%

“…However, when the role of this cytokine in the pathogenesis of insulin resistance, type 2 diabetes or atherosclerosis [122,125,130] is taken under consideration, it cannot be excluded that elevated circulating levels of IL-8 in patients with psoriasis may contribute to the maintenance of the inflammation, which plays a vital role in the pathogenesis of metabolic syndrome.…”

Section: Interleukin-8 (Il-8)mentioning

confidence: 99%

Biochemical markers of psoriasis as a metabolic disease

Gerkowicz

Pietrzak

Szepietowski

et al. 2012

Folia Histochem Cytobiol.

View full text Add to dashboard Cite

Psoriasis is a chronic immune mediated inflammatory skin disease with a population prevalence of 2-3%. In recent years, psoriasis has been recognized as a systemic disease associated with metabolic syndrome or its components such as: obesity, insulin resistance, hypertension and atherogenic dyslipidemia. Many bioactive substances have appeared to be related to metabolic syndrome. Based on current literature, we here discuss the possible role of adiponectin, leptin, ghrelin, resistin, inflammatory cytokines, plasminogen activator inhibitor 1, uric acid, C-reactive protein and lipid abnormalities in psoriasis and in metabolic syndrome.

show abstract

Involvement of leukotactin-1, a novel CC chemokine, in human atherosclerosis

Cited by 31 publications

References 29 publications

Human LZIP induces monocyte CC chemokine receptor 2 expression leading to enhancement of monocyte chemoattractant protein 1/CCL2-induced cell migration

Human LZIP induces monocyte CC chemokine receptor 2 expression leading to enhancement of monocyte chemoattractant protein 1/CCL2-induced cell migration

Circulating levels of MCP-1 and IL-8 are elevated in human obese subjects and associated with obesity-related parameters

Biochemical markers of psoriasis as a metabolic disease

Contact Info

Product

Resources

About